Loading
A phase 2 trial of Tiragolumab, Pembrolizumab, Axitinib in renal cell carcinoma, run by Hoffmann-La Roche, active and no longer recruiting.
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma is a phase 2 interventional study registered as NCT05805501 by Hoffmann-La Roche, with 199 participants enrolled, started 2023-04-21 and due to reach its primary completion in 2026-10-08. Interventions recorded: Tobemstomig, Tiragolumab, Pembrolizumab, Axitinib. Conditions listed: Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.
Shares Axitinib, Renal cell carcinoma, Pembrolizumab, Small-molecule kinase inhibitors.
Shares Axitinib, Renal cell carcinoma.
Shares Axitinib, Pembrolizumab.
Shares Tiragolumab, Roche / Genentech, Anti-angiogenic therapy.
Shares Axitinib, Pembrolizumab.
Shares Tiragolumab, Roche / Genentech.
Shares Tiragolumab, Roche / Genentech.
Shares Roche / Genentech, Anti-angiogenic therapy.